Similar articles

• Erythropoietin: high profile, high scrutiny.

  Crawford J. Crawford J. J Clin Oncol. 2007 Mar 20;25(9):1021-3. doi: 10.1200/JCO.2006.08.8153. Epub 2007 Feb 20. J Clin Oncol. 2007. PMID: 17312331 No abstract available.
• Development of a strategy to successfully convert an ambulatory infusion center from epoetin alfa to darbepoetin alfa.

  Longfield V, Gebhart B, Hayward L. Longfield V, et al. J Support Oncol. 2005 Nov-Dec;3(6 Suppl 4):8-9. J Support Oncol. 2005. PMID: 16355548 No abstract available.
• New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.

  Steensma DP. Steensma DP. J Support Oncol. 2007 Nov-Dec;5(10):471-3. J Support Oncol. 2007. PMID: 18240668 No abstract available.
• Erythropoietin-stimulating agents: new data yield new insights.

  Zitella L. Zitella L. Oncology (Williston Park). 2007 Oct;21(11 Suppl Nurse Ed):36-8. Oncology (Williston Park). 2007. PMID: 18154208 Review. No abstract available.
• Darbepoetin alpha coming of age.

  Pedrazzoli P, Cinieri S, Lorusso V, Gamucci T, Secondino S, Silvestris N. Pedrazzoli P, et al. Anticancer Res. 2007 Nov-Dec;27(6C):4419-24. Anticancer Res. 2007. PMID: 18214054 Review.